Literature DB >> 28131742

JAK/STAT disruption induces immuno-deficiency: Rationale for the development of JAK inhibitors as immunosuppressive drugs.

Isabelle Cornez1, Sowmya Parampalli Yajnanarayana1, Anna Maria Wolf1, Dominik Wolf2.   

Abstract

Cytokines are mediating immune cells responses through the activation of the JAK/STAT signaling pathway. Being critical for immune cells, a defective JAK/STAT signaling leads to various immune disorders, such as immunodeficiency. In contrast, hyperactivation of JAK/STAT signaling is linked to autoimmunity and cancer. Targeting the JAK/STAT proteins by small protein inhibitors impedes immune cell function by uncoupling cells from cytokine effects and by interfering with functional immune cell hallmarks, such as cell migration. This review will explore immune syndromes driven by JAK/STAT deregulation and discuss the emerging role of JAK inhibitors as immunosuppressive drugs used in autoimmunity and transplantation medicine.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autoimmunity; GVHD; Immunosuppression; JAK; Myeloproliferative neoplasia; STAT

Mesh:

Substances:

Year:  2017        PMID: 28131742     DOI: 10.1016/j.mce.2017.01.035

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  9 in total

Review 1.  Progress in Immunosuppressive Agents for Solid-Organ Transplantation.

Authors:  Wynne Qing Zhang; John M Vierling
Journal:  Tex Heart Inst J       Date:  2019-02-01

2.  Ruxolitinib inhibits cyclosporine-induced proliferation of cutaneous squamous cell carcinoma.

Authors:  Melody Abikhair Burgo; Nazanin Roudiani; Jie Chen; Alexis L Santana; Nicole Doudican; Charlotte Proby; Diane Felsen; John A Carucci
Journal:  JCI Insight       Date:  2018-09-06

3.  JAK2 and PTPRC mRNA expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus.

Authors:  Danfeng Qian; Lu Liu; Tingting Zhu; Leilei Wen; Zhengwei Zhu; Xianyong Yin; Ying Qiu; Mingshun Wu; Xueying Li; Jie Ma; Qun Zhang; Ling Jin; Xiaomeng Wang; Qiaohu Xu; Sen Yang; Yujun Sheng; Shengquan Zhang; Xuejun Zhang
Journal:  Clin Rheumatol       Date:  2019-11-23       Impact factor: 2.980

4.  High-throughput screening for small molecule inhibitors of the type-I interferon signaling pathway.

Authors:  Elita Yuliantie; Xinchuan Dai; Dehua Yang; Peter J Crack; Ming-Wei Wang
Journal:  Acta Pharm Sin B       Date:  2018-07-10       Impact factor: 11.413

5.  The effect of Ganoderma lucidum extract on immunological function and identify its anti-tumor immunostimulatory activity based on the biological network.

Authors:  Ruolin Zhao; Qilong Chen; Yu-Min He
Journal:  Sci Rep       Date:  2018-08-23       Impact factor: 4.379

Review 6.  Established and Emerging Concepts to Treat Imbalances of Iron Homeostasis in Inflammatory Diseases.

Authors:  Verena Petzer; Igor Theurl; Günter Weiss
Journal:  Pharmaceuticals (Basel)       Date:  2018-12-11

Review 7.  JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression.

Authors:  Katie L Owen; Natasha K Brockwell; Belinda S Parker
Journal:  Cancers (Basel)       Date:  2019-12-12       Impact factor: 6.639

8.  Bridging Radiotherapy to Immunotherapy: The IFN-JAK-STAT Axis.

Authors:  Lewis Zhichang Shi; James A Bonner
Journal:  Int J Mol Sci       Date:  2021-11-14       Impact factor: 5.923

9.  Treatment with a JAK1/2 inhibitor ameliorates murine autoimmune cholangitis induced by IFN overexpression.

Authors:  Tihong Shao; Patrick S C Leung; Weici Zhang; Koichi Tsuneyama; William M Ridgway; Howard A Young; Zongwen Shuai; Aftab A Ansari; M Eric Gershwin
Journal:  Cell Mol Immunol       Date:  2022-08-30       Impact factor: 22.096

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.